|
1
|
Wang J, Zhang ZQ, Li FQ, Chen JN, Gong X,
Cao BB and Wang W: Triptolide interrupts rRNA synthesis and induces
the RPL23MDM2p53 pathway to repress lung cancer cells. Oncol Rep.
43:1863–1874. 2020.PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Morgensztern D, Campo MJ, Dahlberg SE,
Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist
RS, Hensing T, et al: Molecularly targeted therapies in
non-small-cell lung cancer annual update 2014. J Thorac Oncol. 10
(Suppl 1):S1–S63. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Janssen-Heijnen ML, van Erning FN, De
Ruysscher DK, Coebergh JW and Groen HJ: Variation in causes of
death in patients with non-small cell lung cancer according to
stage and time since diagnosis. Ann Oncol. 26:902–907. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zappa C and Mousa SA: Non-small cell lung
cancer: Current treatment and future advances. Transl Lung Cancer
Res. 5:288–300. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fennell DA, Summers Y, Cadranel J, Benepal
T, Christoph DC, Lal R, Das M, Maxwell F, Visseren-Grul C and Ferry
D: Cisplatin in the modern era: The backbone of first-line
chemotherapy for non-small cell lung cancer. Cancer Treat Rev.
44:42–50. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Perse M and Večerić-Haler Z:
Cisplatin-induced rodent model of kidney injury: Characteristics
and challenges. Biomed Res Int. 2018:14628022018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kartalou M and Essigmann JM: Mechanisms of
resistance to cisplatin. Mutat Res. 478:23–43. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rocha CRR, Silva MM, Quinet A, Cabral-Neto
JB and Menck CFM: DNA repair pathways and cisplatin resistance: An
intimate relationship. Clinics (Sao Paulo). 73 (Suppl 1):e478s2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kasof GM, Goyal L and White E: Btf, a
novel death-promoting transcriptional repressor that interacts with
Bcl-2-related proteins. Mol Cell Biol. 19:4390–4404. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sarras H, Azami SA and McPherson JP: In
search of a function for BCLAF1. ScientificWorldJournal.
10:1450–1461. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wen Y, Zhou X, Lu M, He M, Tian Y, Liu L,
Wang M, Tan W, Deng Y, Yang X, et al: Bclaf1 promotes angiogenesis
by regulating HIF-1α transcription in hepatocellular carcinoma.
Oncogene. 38:1845–1859. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vohhodina J, Barros EM, Savage AL,
Liberante FG, Manti L, Bankhead P, Cosgrove N, Madden AF, Harkin DP
and Savage KI: The RNA processing factors THRAP3 and BCLAF1 promote
the DNA damage response through selective mRNA splicing and nuclear
export. Nucleic Acids Res. 45:12816–12833. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li X, He Z, Cheng B, Fang Q, Ma D, Lu T,
Wei D, Kuang X, Tang S, Xiong J and Wang J: Effect of BCLAF1 on
HDAC inhibitor LMK-235-mediated apoptosis of diffuse large B cell
lymphoma cells and its mechanism. Cancer Biol Ther. 19:825–834.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee YY, Yu YB, Gunawardena HP, Xie L and
Chen X: BCLAF1 is a radiation-induced H2AX-interacting partner
involved in γH2AX-mediated regulation of apoptosis and DNA repair.
Cell Death Dis. 3:e3592012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Savage KI, Gorski JJ, Barros EM, Irwin GW,
Manti L, Powell AJ, Pellagatti A, Lukashchuk N, McCance DJ,
McCluggage WG, et al: Identification of a BRCA1-mRNA splicing
complex required for efficient DNA repair and maintenance of
genomic stability. Mol Cell. 54:445–459. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Carmody SR and Wente SR: mRNA nuclear
export at a glance. J Cell Sci. 122:1933–1937. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang F, Wu J and Yu X: Integrator3, a
partner of single-stranded DNA-binding protein 1, participates in
the DNA damage response. J Biol Chem. 284:30408–30415. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen P, Li J, Chen YC, Qian H, Chen YJ, Su
JY, Wu M and Lan T: The functional status of DNA repair pathways
determines the sensitization effect to cisplatin in non-small cell
lung cancer cells. Cell Oncol (Dordr). 39:511–522. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qin C, Zhang R, Lang Y, Shao A, Xu A, Feng
W, Han J, Wang M, He W, Yu C and Tang J: Bclaf1 critically
regulates the type I interferon response and is degraded by
alphaherpesvirus US3. PLoS Pathog. 15:e10075592019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kinner A, Wu W, Staudt C and Iliakis G:
Gamma-H2AX in recognition and signaling of DNA double-strand breaks
in the context of chromatin. Nucleic Acids Res. 36:5678–5694. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fragkos M, Jurvansuu J and Beard P: H2AX
is required for cell cycle arrest via the p53/p21 pathway. Mol Cell
Biol. 29:2828–2840. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang A, Ning Z, Lu C, Gao W, Liang J, Yan
Q, Tan G and Liu J: USP22 induces cisplatin resistance in lung
adenocarcinoma by regulating γH2AX-mediated DNA damage repair and
Ku70/Bax-mediated apoptosis. Front Pharmacol. 8:2742017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Meng X, Yang S and Camp VJA: The interplay
between the DNA damage response, RNA processing and extracellular
vesicles. Front Oncol. 9:15382020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang Y, Liu C, Zeng WC, Xu GY, Wu JM, Li
ZW, Huang XY, Lin RJ and Shi X: Isoliquiritigenin inhibits the
proliferation, migration and metastasis of Hep3B cells via
suppressing cyclin D1 and PI3K/AKT pathway. Biosci Rep.
40:BSR201927272020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen S, Zhou Q, Guo Z, Wang Y, Wang L, Liu
X, Lu M, Ju L, Xiao Y and Wang X: Inhibition of MELK produces
potential anti-tumour effects in bladder cancer by inducing G1/S
cell cycle arrest via the ATM/CHK2/p53 pathway. J Cell Mol Med.
24:1804–1821. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kreis NN, Louwen F and Yuan J: The
multifaceted p21 (Cip1/Waf1/CDKN1A) in cell differentiation,
migration and cancer therapy. Cancers (Basel). 11:12202019.
View Article : Google Scholar
|
|
31
|
Dell'Aversana C, Giorgio C, D'Amato L,
Lania G, Matarese F, Saeed S, Costanzo AD, Petrizzi VB, Ingenito C,
Martens JHA, et al: miR-194-5p/BCLAF1 deregulation in AML
tumorigenesis. Leukemia. 31:2315–2325. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li HL, Wang CY, Fu J, Yang XJ, Sun Y, Shao
YH, Zhang LH, Yang XM, Zhang XL and Lin J: PTEN expression in U251
glioma cells enhances their sensitivity to ionizing radiation by
suppressing DNA repair capacity. Eur Rev Med Pharmacol Sci.
23:10453–10458. 2019.PubMed/NCBI
|
|
33
|
Kamarudin MNA, Sarker MMR, Zhou JR and
Parhar I: Metformin in colorectal cancer: Molecular mechanism,
preclinical and clinical aspects. J Exp Clin Cancer Res.
38:4912019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yilmaz TE, Taşdemir M, Kaya M, Arican N
and Ahishali B: The effects of magnesium sulfate on
cyclophosphamide-induced ovarian damage: Folliculogenesis. Acta
Histochem. 122:1514702020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Warfel NA and El-Deiry WS: p21WAF1 and
tumourigenesis: 20 years after. Curr Opin Oncol. 25:52–58. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Abbas T and Dutta A: p21 in cancer:
Intricate networks and multiple activities. Nat Rev Cancer.
9:400–414. 2009. View Article : Google Scholar : PubMed/NCBI
|
